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Introduction 
Since the initial description of a pteridine (Fig. 1) in 
Nature 112 years ago,(1) numerous studies contributed 
to the current understanding of these small molecules 
as ubiquitous and essential compounds required for 
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Figure 1. Chemical structures . "Pteridine" denotes the pyrazino-2,3-d-pyrimidine ring system underlying these 
molecules. The majority of the naturally occurring unconjugated pteridines, e.g. biopterin, neopterin, or sepi-
apterin, are derivatives of the 2-amino-4-oxo-pteridine, and this bicyclic basic structure has been termed "pterin" . 
Note that sepiapterin is not synthesized in mammals including man. Besides unconjugated pteridines , also con-
jugated pteridines are widely distributed in nature . Certainly the most important are folates , a g1'OUp of hetero-
cyclic compounds based on the 4-[(pteridin-6-ylmerhyl lamino ]benzoic acid skeleton conjugated with one or more 
L-glutamate units. 
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abundant cellular functions in plants, bacteria, non-
mammals, and mammals. 
In man, tetrahydrobiopterin (BH4) is the predominant 
and most important pteridine. Research on BH4 frrst 
focused on the recognized cofactor function during 
aromatic amino acid hydroxylation and diseases asso-
ciated with inborn errors of BH4 metabolism.2 
However, a century after the publication of Hopkins' 
short notice, it was apparent that BH4 has additional 
metabolic roles, and major investigators' interest 
turned to the relationship between these compounds 
and the immune system.(2) A link was made with the 
observation that BH4 is also essentially required for 
synthesis of nitric oxide (NO),(3-6) a lipid- and water-
soluble gas believed to be central for host defense.(7;8) 
Concomitantly, a pivotal role of NO in the control of 
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reviews.(2;12-23) At the tl..I rn of the millenium, how-
ever, a number of important questions remain unan-
swered certainly stimulating future work in this field. 
Materials and Methods 
BIOSYNTHESIS OF BHJAND ITS REGULATION 
The molecular basis ofBH4 biosynthesis and regen-
eration has been characterized in detail. Today, stuc-
tures and kinetics of involved enzymes are known, and 
corresponding human genes have been localized and 
cloned; for recent review see.( 13) 
BH4 biosynthesis and regeneration (Fig. 2) 
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Figure 2 . BH4 biosynthesis, salvage pathway, and regeneration. See text for details. De novo biosynthesis starts 
from GTP. Sepiapterin is not synthesized in mammalian cells, but is taken up by an yet unknown mechanism. 
BH4 oxidized during aromatic amino acid hydroxylation is recycled by a separate enzyme system. Abbreviations: 
AAAH, aromatic amino acid hydroxylase; DHFR, dihydrofolate reductase; DHPR, dihydropteridine reductase; 
GTPCH, GTP cyclohydrolase I; PCDIDCoH, pterin-4a-carbinolamine dehydratase; PTPS, 6-pyruvoyl-tetrahy-
dropterin synthase; SR, sepiapterin reductase. 
vascular tone became established as well,(9-11) and 
soon data indicated that BH4 might playa critical role 
in the vascular system. This review will focus on that 
role of BH4 with emphasis on human experimental and 
clinical studies and will discuss the potential of BH4 as 
novel treatment modality for vascular disorders. Other 
facets of BH4 biology have been covered in recent 
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requires three main enzymatic steps. In a first step, 
GTP is cleaved by GTP cyclohydrolase I (GTPCH) to 
yield 7,8-dihydroneopterin triphosphate in a complex 
catalytic mechanism resulting in several intermediates. 
7,8-dihydroneopterin triphosphate is then converted to 
6-pyruvoyl-5,6,7,8-tetrahydropterin (PTP) in a ZnH -
and Mg" -dependent reaction by 6-pyruvoyl tetrahy-
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dropterin synthase (PTPS) without the need for exter-
nal reducing agents . Finally, sepiapterin reductase 
(SR) catalyzes the reduction of the two side-chain keto 
groups of PTP to BH4 in a two-step reaction each 
requiring NADPH as a redox cofactor. 
Regeneration of BH4. During the catalytic process 
of amino acid hydroxylases, BH4 is oxidized to BH4-
4a-carbinolarnine.This compound is further dehydrat-
ed to quinoid dihydrobiopterin by pterin-4a-carbino-
lamine dehydratase (PCDIDCoH). Finally, the dimeric 
dihydropteridine reductase (DHPR) reduces quinoid 
dihydrobiopterin back to BH4 in a NADH-dependent 
reaction . 
Salvage pathway. Via the pterin salvage pathway, 
preexisting 7,8-BH2 and sepiapterin, a pteridine not 
naturally occuring in mammals, can be converted to 
BH4 Sepiapterin is converted to 7,8-BH2 by SR. In the 
final step, BH4 is formed in a NADPH-dependent reac-
tion by dihydrofolate reductase (DHFR). 
Regulation of enzyme activity involved in BH4 bio-
synthesis and regeneration 
GTPCH is commonly thought to be the rate-limiting 
enzyme in de novo BH4 biosynthesis. Its activity is 
regulated at the transcriptional and post-translational 
level as well as via GTPCH feedback regulatory pro-
tein (GFRP) which modulates enzymatic activity by 
inducing an conformational change of GTPCH. 
: ~gulation at the transcriptional level by pro- and anti-
.:-. tlanunatory cytokines or endotoxin may be remark-
able and the predominant mechanism for modulation 
of enzymatic activity. Compared to rodent cells, 
human cells have much lower PTPS activity. 
Therefore, 7,8-dihydroneopterin triphosphate is not 
efficiently converted into BH4 but is partially dephos-
phorylated to 7,8-dihydroneopterin by cellular phos-
phatases and further oxidized to neopterin. The rate-
limiting effect of PTPS in human cells is reflected by 
accumulation of neopterin following immunostimula-
tory induction of GTPCH activity. Very recently, a 
cytokine-dependent regulation of PTPS mRNA abun-
dance and specific activity in human vascular endothe-
lial cells that prevents neopterin accumulation has been 
shown. In contrast, no significant modulation of enzy-
matic activity of SR has been found in vivo so far, 
although in vitro studies showed modification of kinet-
ic properties following phosphorylation. Whether the 
enzymatic activity of PCDIDCoH, DHPR, or DHFR is 
regulated to a clinically important degree is unknown 
at present.( 13; 17;21) 
FUNCTIONS OF BH. 
BH4 as substrate of aromatic amino acid hydroxy 
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lases 
Phenylalanine hydroxylase, tyrosine 3-hydroxylase, 
and tryptophan 5-hydroxylase constitute a family of 
enzymes which are central to normal physiology 
because they modulate the production of neurotrans-
mitters and hormones such as dopamine, norepineph-
rine, epinephrine, serotonin, and melatonin. ( 15;24;25) 
These homotetrameric enzymes have a strict require-
ment for pteridines, oxygen, and iron. BH4 has been 
identified as the naturally occurring cofactor, but a 
variety of substitutes at different positions of the pterin 
ring are tolerated by at least one of the monooxyge-
nases. The pyrimidine, but not the complete pyrazine 
ring is required for enzymatic activity. During cataly-
sis, one atom of oxygen from molecular oxygen is 
incorporated into the substrate and the other atom 
reduced to water. BH4, which acts as substrate rather 
than tightly bound cofactor, supplies both electrons 
required for the reduction of the second atom of water. 
One of the oxidation products of the catalytic reaction 
by all three hydroxylases is BH4-4a-carbinolamine, 
which is subsequently regenerated by the enzymes 
PCD/DCoH and DHPR. 
Phenylalanine hydroxylase is allosterically regulat-
ed by phenylalanine and BH4. Whereas phenylalanine 
is a positive allosteric effector that converts the inac-
tive enzyme to a catalytically active form, BH4 is a 
negative effector that competes with phenylalanine to 
form a dead-end complex with the inactive en-
zyme.(26;27) A further regulation of phenylalanine 
hydroxylase activity is achieved by phosphorylation of 
a serine residue resulting in a shift of the balance 
between the active and inactive form of the enzyme 
towards the active form. BH4 has been recognized to 
inhibit this phosphorylation. ( 15) All amino acid 
hydroxylases are inhibited by catecholamines, but only 
the inhibition of human tyrosine hydroxylase is com-
petitive with respect to BH4. 
BH4 as cofactor for NO synthase (NOS) 
Catalysis by NOS (EC 1.14.13.39) is complex and 
molecular details of the reaction mechanism remain 
elusive; for recent comprehensive reviews see.28-34 
The NOS family comprises at least three distinct 
homodimeric enzymes: neuronal (nNOS, NOS 1), 
inducible (iNOS, NOS2) and endothelial (eNOS, 
NOS3). They have considerable similarity in catalytic 
function and share about 50% homology in their amino 
acid sequences. NOSs exhibit spectroscopic and cat-
alytic properties strongly reminiscent of those of 
cytochrome P450 reductase and are members of the 
heme-thiolate family of proteins that also includes 
P450. 
NOS catalyzes the five electron oxidation of one of 
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the chemically equivalent guanidino-nitrogens of L-
arginine in a two-step process to finally yield L-cit-
rulline and NO via N"-hydroxy-L-arginine as tightly-
bound intermediate. Due to the labile nature of NO, 
direct evidence that purified NOS directly synthesize 
NO has only recently been provided by electron para-
magnetic resonance spectroscopy.(35) 
NOS isoforms differ primarily with respect to sub-
cellular localization, expressional regulation, post-
translational modifications, and activity modulation. 
nNOS contains a PDZ binding motif (found in a num-
ber of proteins implicated in ion-channel and receptor 
clustering, and the linking of receptors to effector 
enzymes. PDZ domains are protein-recognition mod-
ules) at the amino terminus that is involved in subcel-
lular targeting of the protein, and eNOS is distin-
guished by the presence of myristoylation, palmitoyla-
tion, famesylation, acetylation, and phosphorylation 
sites at the amino terminus that serve a similar func-
tion. Depalmitoylation of eNOS promotes the dissoci-
ation of the enzyme from its proximity to activating 
molecules localized in the membrane and may serve as 
a feedback mechansim leading to eNOS deactivation. 
eNOS and nNOS are considered constitutive and par-
ticipate in signal cascades by synthesizing NO depend-
ing upon elevation of intracellular calcium. Main reg-
ulation of enzymatic activity occurs post-translational-
ly. iNOS is expressed in various cell types in response 
to certain stimuli, such as inflammatory cytokines or 
bacterial cell products , and its regulation occurs most-
ly at the level of transcription. With tightly bound 
calmodulin, iNOS is fully active at basal calcium le-
vels. 
In all NOS isoforms, BH4, heme (iron protopor-
phyrin IX), flavin mononucleotide (FMN), and flavin 
adenin dinucleotide (FAD) are required as cofactors, 
molecular oxygen is used as cosubstrate, and NADPH 
donates the reducing equivalents necessary for enzy-
matic activity. Each monomer has two domains: a N-
terminal oxygenase domain (containing BH4 and 
heme) and a C-terminal reductase domain (containing 
FAD and FMN) linked by a calmodulin-binding con-
sensus sequence. All NOS isoforms dimerize through 
the heme domain. An unified model has been proposed 
to explain the enzymatic mechanisms of NOSs. 
Critical to NOS catalysis is the transfer of electrons 
from NADPH to heme. Binding of calmodulin serves 
to position the two domains and promotes the flow of 
NADPH-derived electrons from the flavins to the 
heme, which is thought to activate oxygen and to initi-
ate NO synthesis. Maximum rate of NO synthesis by 
eNOS is severalfold slower than that of nNOS or 
iNOS, primarily due to low intrinsic reductase activity 
that limits both the delivery of electrons to the heme 
PtcridincsIVol. l2lNo. 3 
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and overall activity of the enzyme. 
BH4 is absolutely required in the catalytic reaction 
ofNOS,(3-6) however. the exact role in the enzymatic 
process is still incompletely understood. It binds by 
hydrogen bridges with a heme propionate in a pocket 
situated between monomers where it interacts with 
residues from each subunit, and may thereby stabilize 
the dimeric form of the enzyme. In fact, BH4 together 
with the substrate L-arginine promotes the dimeriza-
tion of iNOS and stabilizes the nNOS dimer; however, 
it does not seem to be required for the dimerization of 
eNOS. Modulation of NOS activity by BH4 is exclu-
sively mediated through interactions with the heme 
domain. Both the pteridine cofactor and L-arginine 
interact with the same heme propionate which explains 
the interplay between BH4 and substrate binding. 
Indeed, allosteric effects of BH4 on NOS have long 
been described. BH4 triggers the conversion of the 
inactive low-spin to the active high-spin confom1ation 
of the enzyme, and BH4 interacts with L-arginine by 
positive cooperativity. An unusual aspect of BH4 bind-
ing is that two identical but highly anticooperative 
binding sites for BH4 have been found for nNOS and 
iNOS. With binding of a first BH4 to the NOS dimer, 
one L-arginine is tightly bound, and this greatly weak-
ens the affinity of the second BH4 and L-arginine bind-
ing sites in the NOS dimer for both, BH4 and L-argi-
nine, respectively. It is therefore possible that NOS 
could contain only one BH4 per dimer in some biolog-
ical settings. For human nNOS, dual allosteric interac-
tions between BH4 binding site and L-arginine-binding 
site have been confirmed. BH4 binding not only 
increases enzyme activity but also decreases the appar-
ent Km for L-arginine, and, conversely, L-arginine 
activates human nNOS by allosterically 
modulating/increasing the affinity for binding of BH4. 
The 1,2-dihydroxypropyl side chain at the 6-position 
has been suggested to promote cooperativity of 
BH4.(36) 
Recent data indicate a redox-active role of BH4 in 
the NOS reaction . Experiments with BH4-free NOS 
indirectly implicate the reduced pteridine cofactor in 
the first step of the reaction. Together with the newly 
recognized participation ofnonheme ferrous iron in the 
reaction, the current information raise the possibility 
that the pteridine may act in this step in an analogous 
fashion to that characterized for the amino acid 
hydroxylases. Furtheml0re, it has been established that 
BH4 promotes the transition of the heme group from 
low to high spin-state thereby facilitating electron 
transfer from the flavoprotein domain resulting in the 
reduction of heme-iron trom ferric to the ferrous form, 
which is required for the conversion of L-arginine to 
N"'-hydroxy-L-arginine. Critical to all mechanistic 
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considerations is the formation of the ferrous-dioxygen 
NOS complex during the second step of NOS cataly-
sis. BH4 decreases the lifetime of this complex (as 
shown for nNOS) and may therefore influence the 
course of the reaction by affecting electron transfer. 
Recent low temperature experiments suggested that 
BH4 may donate an electron required for activation of 
the ferrous dioxygen complex thereby generating a 
pteridine radical, which is rapidly reduced intraen-
zymical\y thereafter as part of the NOS catalytic cycle. 
Enzyme-generated NO can bind to the NOS heme 
and influence subsequent catalysis in a reversible man-
ner as the NO-bound form is inactive ("NO feedback 
inhibition"). Both iNOS and nNOS intrinsically form 
heme-NO complexes during NO synthesis, and a 
majority of enzyme may partition into the inactive 
form due to insufficiently slow dissociation of NO 
from NOS. BH4 has been shown to attenuate NO feed-
back inhibition thereby stimulating enzymatic activity. 
Possible mechanisms may include removal of NO by 
reaction with superoxide formed in the course of BH4 
autoxidation, and destabilization of the heme-NO com-
plex. In contrast, little or no NO complex is formed 
during NO generation from eNOS, most probably due 
to slow electron transfer between flavins and heme 
resulting in a low NO concentration. These findings 
indicate that NO feedback inhibition has a minimal 
role in eNOS catalysis.(37) 
Recent data suggest that intracellular BH. availabil-
ity may regulate iNOS mRNA and protein expression. 
This effect appears to be mediated, at least in part, by 
an increase in iNOS rnRNA stability.(38;39) 
An important aspect of NOS catalysis is the fonnu-
tion of oxygen-derived free radicals as a general fea-
ture of all NOSs which has been studied over the 
recent years in detail by use of electron paramagnetic 
resonance spin-trapping experiments with purified 
NOS. Evidence indicates that BH4 plays a critical role 
not only in increasing the rate of NO generation but 
also in controlling the formation of superoxide and 
hydrogen peroxide by NOS. 
Besides synthesizing NO, nNOS can catalyze 
superoxide formation at low levels of L-arginine in a 
calcium/calmodulin-dependent process.(35;40-42) In 
vitro studies using nNOS transfected cells showed that 
NO production declined with L-arginine depletion 
whereas the production of superoxide increased, and 
this switch of NOS from the production of NO to 
superoxide crucially depended on intracellular levels 
of L-arginine.( 43) The source of superoxide remains 
unclear. Some investigators suggested the formation of 
superoxide at the oxygenase domain ofnNOS, where-
as others implicated the reductase domain of nNOS, or 
both.(44) 
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L-arginine controls the generation of superoxide by 
decreasing the rate of NADPH consumption.(44) In 
assays with purified nNOS protein, superoxide may 
also be generated by the reductive reaction of high 
concentrations of FAD with NADPH.(35) In addition, 
in the presence of a redox-cycling compound such as 
FMN, nNOS increases the generation of superoxide in 
a calcium/calmodulin-independent manner.(44) 
Occupation of the L-arginine binding site may sta-
bilize the fenic superoxide complex,( 45) and the pre-
vention of dissociation of this complex is proposed to 
decrease the generation of superoxide both from the 
oxygenase and reductase domains of nNOS.( 44) 
Pteridine-free purified nNOS generates superoxide 
from the reductase and the oxygenase domain by a cal-
cium/calmodulin-dependent mechanism. Generation 
of superoxide by this pathway in tightly controlled by 
BH4, possibly by promoting the fonnation of heme-
peroxo species. In the presence of both L-arginine and 
BH4, the formation of the oxoferryl will occur thereby 
facilitating the oxidation of L-arginine to generate N?-
hydroxy-L-arginine.44 BH4 and L-arginine also stabi-
lize dimeric nNOS during catalysis and markedly 
inhibit monomerization, thereby reducing enzyme 
inactivation induced by the generation of reactive oxy-
gen species. It has been proposed that BH4 may direct-
ly scavenge excessively generated superoxide and sub-
sequently degrade to yet unknown products in situa-
tions when L-arginine levels are limiting.(36) 
Hydrogen peroxide may be formed by nNOS by 
two different mechanisms depending on the availabili-
ty of BH4. At low BH4 concentrations, nNOS will gen-
erate only superoxide that, by dismutation, will pro-
duce hydrogen peroxide and oxygen. In the presence 
of BH4, however, no superoxide will be formed, and 
the enzyme will generate hydrogen peroxide by a 
mechanism involving a two-electron reduction of oxy-
gen.(44) BH4 decreases the generation of hydrogen 
peroxide by nNOS while increasing L-citrulline for-
mation.{ 41 ;46) 
Superoxide and NO synthesis can also occur simul-
taneously within iNOS in experiments with purified 
protein,(47) and in L-arginine depleted macrophages 
iNOS has been shown to generate peroxynitrite,(48) a 
powerful oxidant with a relatively long half-life that is 
formed at a diffusion-limited rate from NO and super-
oxide .(49) Superoxide generation mainly occurs at the 
flavin-binding sites of the reductase domain.( 47) In 
experiments using BH4-free iNOS expressed in E. coli, 
BH4 shifted iNOS from a superoxide producing to a 
peroxynitrite producing enzyme in the absence of 
superoxide dismutase (SOD, EC 1.15.1.1); only the 
addition of SOD resulted in a detectable NO sig-
na\.(50) 
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iNOS and nNOS exhibit very different L-arginine-
dependent inhibition of superoxide generation. 
Inhibition of superoxide generation from iNOS was 
only seen at high L-arginine concentrations, whereas 
low L-arginine levels completely block superoxide for-
mation from nNOS.(41;47) The reason for this differ-
ence is not yet clear. However, it has been concluded 
that because of relative high cytosolic levels of L-argi-
nine, superoxide generation would rarely occur with 
nNOS, whereas the simultaneous NO and superoxide 
generation from iNOS may be beneficial since these 
two free radicals will interact to form the more potent 
toxic oxidant peroxynitrite which will prevent feed-
back inhibition of iNOS and may enhance killing 
activity by iNOS.(47) 
Superoxide can be generated by eNOS in a calci-
Um/calmodulin-dependent manner from the dissocia-
tion of a transient heme ferrous-dioxygen complex in 
the oxygenase domain of eNOS. BH4 dose-dependent-
ly decreases superoxide levels both by coupling L-
arginine oxidation to NADPH consumption and by 
direct scavenging properties. In contrast to the effect of 
BH4, L-arginine does not control superoxide genera-
tion and does not interfere with the release of superox-
ide from heme iron. Therefore, eNOS mediated super-
oxide generation is triggered and controlled by 
decreased availability of BH4 rather than L-arginine 
leading to a switch of eNOS from NO to superoxide 
production in states of BH4 depletion.( Sl ;S2) Most 
interestingly, preliminary data indicate that the ratio of 
BH4 to 7,8-BH2 may control superoxide generation as 
BH4-oxidized derivatives compete with BH4 for the 
BH4-binding site at the oxygenase domain of eNOS 
resulting in uncoupling and increased superoxide pro-
duction.(S3) 
NO interacts with various intracellular molecular 
sites within both the generating and target cell, a dis-
tinct NO receptor does obviously not exist. The biolo-
gy of NO signaling has recently been reviewed in 
detail.(S4) Direct effects of NO include interactions 
with transition metals leading to formation of stable 
nitrosyl complexes via covalent reactions between NO 
and metal ions, redox reactions between NO and metal 
ions, and NO binding to iron-sulfur clusters in pro-
teins. Overall, the interaction of NO with the heme 
component of soluble guanylate cyclase with subse-
quent stimulation of enzymatic conversion of GTP to 
cyclic guanosine 3',S'-monophosphate (cGMP) consti-
tutes the major pathway of NO signaling. Other direct 
effects of NO include reactions with free radicals. In 
states of sustained and enhanced NO flux, reactive 
nitrogen species are formed, and indirect effects of NO 
are consequences of S-nitrosation reactions. Most, if 
not all of these indirect effects of NO are dependent on 
PteridineslVol. 121No. 3 
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reactions with oxygen and superoxide, giving rise to 
dinitrogen trioxide and peroxynitrite.(S4) Some of 
these direct and indirect effects of NO in the vascula-
ture are modulated by BH4 and are discussed below. 
BH4 as cofactor for other enzymes 
BH4 is involved in the reactions of at least three 
other enzymes. The reduced pteridine is required by 
the glyceryl-ether mono-oxygenase (EC 1.14.16.S) for 
hydroxylation of the a-carbon atom of the lipid carbon 
chain of glyceryl ether to form a-hydroxyalkyl glyc-
erol.(SS) Furthermore, the dopamine-b-hydroxylase 
(EC 1.14.17.1) in the pathway from dopamine to nora-
drenalin also depends on BH4.(56) Finally, BH4 can 
directly control tyrosinase (EC 1.14.18.1) activity, the 
key enzyme in melanin biosynthesis in melanocytes, 
by uncompetitive inhibition via a specific binding 
domain on the enzyme.(57) BH4 has also been sug-
gested to participate as physiological coenzyme in the 
catalysis of indole amine 2,3-dioxygenase (EC 
1. 13.11.42),(S8;S9) however, these findings have been 
questioned by others.(2) 
Other functions of BH. 
As mentioned above, the first cellular function of 
BH4 recognized was the promotion of growth for the 
protozoon Crithidia fasciculata;(60) microbiological 
assays using the nutritional requirement of this organ-
ism for the L-erythro configuration of biopterin have 
been developed for quantification of this pterin in 
diferent body fluids and tissues and utilized for some 
time; however, they needed a period of several days to 
obtain accurate results, and they were [mally replaced 
by novel and even more sensitive detection teclll1iques, 
e.g. radioimmunoassays, gas chromatography mass 
spectrometry, or high-performance liquid chromatog-
raphy.(61 ;62) 
In addition to its cofactor role for NOSs and aro-
matic amino acid hydroxylases, other functions of BH4 
in the nervous system have been suggested. These 
include a role as a neurotransmitter-releasing factor, 
first demonstrated for dopamine in the rat striatum 
(.63) This effect may be mediated by activation of neu-
ronal calcium channels via cAMP-protein kinase A 
pathway independent of cofactor activity, for recent 
review on the role of BH4 in the nervous system, see 
reference (14). 
It has long been proposed that BH4 may be involved 
in cell proliferation, cell differentiation, and cell-medi-
ated immunity. Such effects have been independently 
observed by several groups, however, the part ofBH4is 
complex and far from being clear.(2;64) Concerning 
the vascular system, BH4 has been shown to stimulate 
in vitro angiogenesis in bovine aortic endothelial cells 
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by yet unclear mechanisms.(65) Nevertheless, it is of 
note that proliferative effects of several growth factors 
seem to depend on an obligatory elevation of intracel-
lular BH4 levels. This has first been shown for epider-
mal growth factor and nerve growth factor on the pro-
liferation of rat phaeochromocytoma PC12 cells.(66) 
BH4-involvement in cell cycle-dependent events by 
affecting c-Myc expression has been described very 
recently.(67) Furthermore, a critical role ofBH4 in the 
signaling cascade of vascular endothelial growth factor 
(YEGF) has been suggested (see below for details) . 
Of major importance for the effect of BH4 in the 
vascular system, especially under pathophysiological 
conditions, is the strong anti oxidative activity of 
reduced pterins; 18 this unspecific function of BH4 will 
be discussed in a later section of this review. 
A modulatory role for BH4 in the expression of of 
cyclooxygenase 2 has been shown for human mesan-
gial cells. In these cells, supplementation with BH4 
potentiated cytokine-induced expression of cyclooxy-
genase 2 in an obviously NO-independent manner. If 
confirmed, these data corroborate the role of BH4 as an 
important cellular mediator molecule in response to 
inflammatory stimuli.(68) 
Finally, recent studies indicated an important role 
for BH4 in regulation of human melanogenesis, for 
which tyrosinase (EC 1.14.18.1) that catalyzes the oxi-
dation of L-tyrosine to the melanin precursor L-
dopaquinone is the key enzyme. The rate of de novo 
melanin synthesis depends on supply of the substrate 
L-tyrosine or direct tyrosinase inhibition/activation. 
The BH4 pathway is induced by UYB irradiation in 
relation to the degree of pigmentation, resulting in 
enhanced phenylalanine hydroxylase activity which 
may in tum supply L-tyrosine within melanocytes. In 
addition, BH4 (but not oxidized forms) directly regu-
lates tyrosinase activity by uncompetitive inhibition. 
The BH4/tyrosinase inhibitor complex can be activated 
either by UYB photooxidation of BH4, or by specific 
complexation with the 13 amino acid peptide a-
melanocyte stimulating hormone (a-MSH). a-MSH, 
which is present in melanocytes, forms a specific and 
stable 1: 1 complex with BH4, thereby protecting the 
pteridine from photo-oxidation. Low levels of a-MSH 
activate phenylalanine hydroxylase, probably by 
removal of BH4 from inactive tetramers of phenylala-
nine hydroxylase to yield active dimers . Since a-MSH 
levels are increased after L \, 13 exposure. a-MSH has 
been postulated as a chaperone for BH" in the human 
epidermis. The redox state of BH~ :nay influence not 
only pigmentation but also melancx: :.1e survival and 
the process of keratinocyte dlfferer.t:atlOll . Pteridines 
are the principal molecules causir:g !t e :luorescence of 
depigmented skin used as a dlagClo5t:.: wo: in the 
99 
depigmentation disorder vitiligo, and major distur-
bances in BH4 metabolism and dependent enzymes 
have been found in vitiligo, eventually induced by epi-
dermal H202 accumulation, but also in the Hermansky-
Pudlak-Syndrome, a rare depigmentation disorder with 
autosomal recessive inheritance; however, the exact 
mechansims underlying these disturbances remain 
uncompletely understood at present.(69-73) 
BH4 AND THE VASCULAR SYSTEM 
Recent years established the importance of BH4 in 
the vascular system in health and disease. Most effects 
were linked to the L-arginine-NO-cGMP signaling 
system, and the vascular endothelium, a dynamic 
organ with vital secretory, metabolic , immunologic, 
and vasoregulative functions ,(74;75) revealed to be 
central for BH4 as a source and functional target of the 
pteridine. Soon after the discovery of an endothelium-
derived relaxing factor (EDRF),(9) it was recognized 
that EDRF has identical properties as NO, a molecule 
known at that time to cause smooth muscle relax-
ation,(76) and EDRF was subsequently proposed to be 
either NO or a very labile nitroso compound readily 
releasing NO.(1 0; 11 ;77) The ubiquity of the NO mol-
ecule has rapidly become clear, and it is now seen as a 
key mammalian metabolite for signaling in biological 
systems.(54;78-83) 
NO maintains basal vessel tone by relaxing vascular 
smooth muscle cells, modulates vascular resistance in 
response to neurohormonal agents or physical forces, 
inhibits interactions between blood cells and vessel 
wall, is involved in the maintenance of vascular 
integrity, and influences proliferation and migration of 
smooth muscle cells.(74;84-86) In the physiologic 
state, vascular endothelial cells of different species 
including man (87-90) constitutively express eNOS 
protein. Endothelium-derived NO diffuses rapidly into 
subjacent vascular smooth muscle, where it binds to 
the heme iron complex of soluble guanylate cyclase 
and stimulates the production of cGMP and relaxation 
of vascular smooth muscle.(54;91) Attention has 
recently focused on the regulatory properties of BH4 
on eNOS activity. 
BH. and the physiologic function of the vascular 
system 
Endothelial cells . Human vascular endothelial cells 
express all enzymes for de novo BH4 biosynthe-
sis.(88 ;92-94) Cellular BH4 turnover may be very 
rapid, as treatment with inhibitors of BH4 biosynthesis 
deplete intracellular BH4 levels within a few 
hours .(92;95) Cultured endothelial cells constitutively 
express GTPCH activity and synthesize small amounts 
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:!- BH" but prolonged culturing seems to cause a 
jec line of intracellular BH4 levels and a disappearance 
of GTPCH activity.(88) Human endothelial cells 
secrete the pteridine,(93;96) possibly vectorially into 
the basal direction.(97) Recently, evidence has been 
Walter R.,.,et al: Tetrahydrobiopterm In 'r:e \ ascular system 
provided that human endothelial cells secrete not the 
fully reduced cofactor, but considerable amounts of 
7,8-BH2 and some biopterin.(96) This finding needs 
confirmation and is somewhat surprismg since in all 
mammalian tissues that have been exammed in vivo 
A Physiological state Human State of inflammation 
B Physiological state Rodents State of inflammation 
Figure 3. "Switch model". Regulation of NOS and BH4 synthetic activity under normal and inflammatory con-
ditions in human (A) and rodents (B). See text for details. 
PteridineslVol. l2INo. 3 
Walter R. el at: Tetrahydrobiopterin in the vascular system 
8S-100% of biopterin present is in the tetrahydro 
fonn.(98;99) 
The signal transduction mechanism for and regula-
tion of gene expression and the reason for the decrease 
of intracellular BH4 during culture is unknown at pres-
ent . However, GTPCH gene expression may be regu-
lated by calcium influx,( I 00) and it is tempting to 
speculate that such a mechanism might be involved. 
In cultured endothelial cells, exogenous sepiapterin 
increases intracellular BH4. The GTPCH inhibitor 2,4-
diamino-6-hydroxypyrimidine (DAHP) significantly 
reduces BH4 levels within these cells which can be 
restored by sepiapterin.(92;9S) These data show 
restoration of intracellular BH4 via activation of the 
salvage pathway demonstrating that precursors ofBH4, 
such as sepiapterin, can be used as pharmacological 
tools to augment the pool of functional pteridine cofac-
tor in vitro. However, the relative importance of this 
pathway in vivo remains unclear. 
The bioavailability of BH4 is pivotal for endothelial 
function, and intracellular BH4 levels potentially regu-
late endothelial NO synthesis and vascular tone 
(88;95;101;102). eNOS activity in freshly isolated or 
cultured human endothelial cells is limited by intracel-
lular Bl-:k(88;96) Pretreatment of cultured cells with 
pro-inflanmmtory cytokines also largely increases 
eNOS activity and histamine-stimulated NO produc-
tion. mainly due to increased GTPCH activity and sub-
sequent elevated BH4Ievels.(88) In contrast, inhibition 
of BH4 synthesis by DAHP reduces endothelial NO 
production.(92;9S;96) 
Smooth muscle cells. Functional de novo BH4 
biosynthetic and salvage pathways have also been 
found in human vascular smooth muscle 
cells .(103;104) However, GTPCH is barely expressed 
in cultured unstimulated human umbilical vein smooth 
muscle cells, only trace amounts of the pteridine are 
measured intracellularly, and no substantial amounts of 
BH4 are secreted. 1 03 Since in cultured human smooth 
muscle cells neither iNOS nor eNOS mRNA is detect-
ed in the resting state,39;87 it can be assumed that BH4 
should have no direct NO-mediated relaxing effect on 
smooth muscle cells under physiologic conditions. 
This is corroborated by results from numerous studies 
which failed to demonstrate an influence of BH4 on 
endothelium-independent relaxation. In addition, the 
availability of BH4 obviously does not affect the reac-
tivity of smooth muscle cells to NO.( 19) Taken togeth-
er, these data indicate that under physiological condi-
tions in man, both NO and BH4 production solely take 
place in the vascular endothelium but not in the under-
lying smooth muscle (Fig. 3A, left side). 
Isolated vessels in vitro and in vivo experiments. 
BH4 is present in intact arteries and veins, and about 
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60% of total BH4 is located within endothelial 
cells.(l02) This may however, not necessarily reflect 
true rates of production since endothelial cells secrete 
BH4 that may be taken up by other cells. Indeed, rat 
smooth muscle cells readily take up BH4 and sepi-
apterin,(39;lOS ;106) and sepiapterin is also taken up 
by human vascular smooth muscle cells .(l04) In line 
with these data are gene transfer experiments demon-
strating that GTPCH activity and resulting BH. does 
not have to coexist in the same cell for the synthesized 
BH4 to support iNOS activity.(l07) Although formal 
proof for BH4 uptake into human smooth muscle cells 
is lacking at the moment, it is conceivable to believe 
that BH4 produced endogenously in vascular endothe-
lial cells or elsewhere in the human body, traffics into 
smooth muscle cells of the vasculature. 
Extending experiments on cultured cells, enhance-
ment of endothelial NO synthesis by exogenous BH4 
could also be demonstrated in isolated vessels in 
vitro,( 10 I) and relaxation was accompanied by dose-
dependent increases of intracellular cGMP levels 
.( 108 )The effect of BH4 on vessels in vitro seem to 
critically depend on experimental conditions, and addi-
tional BH4 may even cause vessel contraction. 
(102;109) a result that has been explained by autoxida-
tion of BH. and generation of superoxide anions.19 
This hypothesis was corroborated by the observatlon 
that superoxide dismutase (SOD) enhanced endotheli-
um-dependent relaxation in arteries with inc reased 
intracellular BH4 levels.(102) 
In vivo data suggest that under physiologic condi-
tions levels of endogenous BH4 are nearly saturating 
and barely a limiting factor for optimal or near optimal 
endothelial eNOS activity,(110-114) and only high 
doses of BH4 may induce a marked local vasodila-
tion.(97; lIS) In contrast to the requirement of rather 
high local BH4 levels for vasodilating effects on the 
systemic circulation in healthy human subjects, 
myocardial blood flow may be increased at doses of 
BH. at which systemic hemodynamics are not affected 
suggesting that different human circuits may be differ-
ently susceptible to exogenous BH4.( 116) 
Endothelium-dependent relaxation mediated by BH. 
under inflammatory conditions . proposal of the 
"switch" model 
The expression of eNOS has traditionally been con-
sidered constitutive, but a multitude of regulating fac-
tors have been recognized.(86;117;118) Pro- and anti-
inflammatory cytokines are probably of pivotal impor-
tance for the regulation of vascular tone under inflam-
matory conditions. Pro-inflammatory cytokines and 
endotoxin may transiently increase NO synthesis in 
human vascular endothelial cells (88;92; 119) by indi-
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rect regulation that includes enhanced synthesis of 
BH4.(92) Nevertheless, there is increasing evidence 
that eNOS is downregulated under inflanunatory con-
ditions. Inflammatory stimuli decrease NO production 
and reduce eNOS protein and mRNA levels in cultured 
endothelial cells, (87-89; 120-123) at least partially due 
to enhanced degradation rates of eNOS tran-
scripts.( 124-126) In contrast, anti-inflanunatory cyto-
kines may induce eNOS mRNA, protein, and activi-
ty.(127) 
Inflammatory stimuli simultaneously induce the 
expression of iNOS mRNA and subsequent "high-out-
put" NO production. Vascular smooth muscle cells 
from different species, including man, express iNOS 
mRNA and functional protein upon stimulation. 
Activation of the L-arginine-NO pathway and iNOS 
expression has been confirmed in human septic shock 
(128), although it has sometimes proved difficult to 
demonstrate a clear role for iNOS in human vessels in 
vivo for cytokine-induced vasodilation and a number 
of human experiments failed to show the consistent 
presence of iNOS under conditions in which this NOS 
isoform is readily induced in animals.(129) Important 
to note that whereas expression of iNOS has also been 
found in murine, swine, bovine, and rat endothelial 
cells,( 123; 130-134) human endothelial cells obviously 
express only eNOS but do not contain any iNOS.(88-
90) Furthermore, no eNOS mRNA is detected neither 
under unstimulated nor under inflammatory conditions 
within human vascular smooth muscle cells.(39;87) 
Culture of vascular cells with inflarnrnatory stimuli 
increases expression of GTPCH, its enzymatic activi-
ty, and subsequently augments intracellular BH4 levels, 
(88;92;105;135) whereas deactivating cytokines effi-
ciently suppress BH4 generation.(93) The increase in 
cellular BH4 is mainly due to induction of de novo 
biosynthesis rather than via the salvage pathway using 
pre-existing dihydropterins.(94; 136) In human vascu-
lar endothelial cells, most of the newly synthesized 
pteridine is secreted into the culture supematant.(93) 
BH4 biosynthesis is essentially required for induction 
of NOS activity, (38;105;137;138) and inhibition of 
BH4 biosynthesis reduces iNOS activity in cytokine-
stimulated cells.(38;105;138-141) Although expres-
sion of GTPCH and iNOS appears to be regulated 
coordinately (135; 142-144) and BH4 contributes to 
enhanced iNOS expression through stabilization of 
iNOS mRNA,(38;39) intrinsic BH4 availability is a 
limiting factor for iNOS activity in many cell types 
including rat smooth muscle cells, (38;105;106; 
137;139;145;146) rendering NO production of these 
cells susceptible to modulation of intracellular BH4 
levels. Treatment with inflammatory stimuli also 
enhances transcription of GTPCH mRNA and increas-
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es intracellular BH4 levels in human umbilical smooth 
muscle cells, and small amounts ofBH4 are also secret-
ed in the culture supernatant;(103) however it remains 
to be demonstrated whether BH4 is also limiting for 
NO synthesis in human smooth muscle cells. 
Activation of BH4 biosynthesis has been confirmed 
in animal experimental sepsis, (144;147-150) and in 
some models biopterin apparently represents a more 
appropriate biochemical marker of septic shock than 
the determination of plasma NOx levels .( I51) The 
regulation of BH4 biosynthesis upon inflammatory 
stimuli in human vessels in vivo remains elusive, how-
ever, the induction of GTPCH in human veins chal-
lenged with cytokines has recently been con-
fIrmed. ( 115) 
Taken the current knowledge together, a "switch" 
model is proposed to summerize changes of regulation 
of NO and BH4 synthesis between physiologic and 
inflammatory conditions in the human vasculature 
(Fig. 3A). Although stimulatory cytokines may 
increase NO synthesis in human vascular endothelial 
cells, the concomitant dramatic decrease of eNOS 
mRNA makes this increase only transient, and a sig-
nificantly reduced NO production is expected to occur 
after a certain time of ongoing inflammation. Thus, it 
must be concluded that NO could only account as an 
EDRF during short term but not during long term 
inflammation in man. Whereas eNOS mRNA and pro-
tein is downregulated, iNOS is induced, e.g. NO pro-
duction switches and is no longer associated with 
eNOS but iNOS activity. Furthermore, the compart-
ment responsible for NO production switches as well. 
Whereas eNOS is located in the vascular endothelium, 
iNOS is expressed in underlying smooth muscle cells. 
In contrast, the vascular endothelium continues to pro-
duce and secrete BH4, and much higher amounts of 
BH4 are secreted under inflammatory conditions . 
Although BH4 synthesis is also induced in underlying 
smooth muscle cells upon inflammatory stimulation, 
these ceIls depend on exogenous BH4 for full iNOS 
activity and readily take up the pteridine cofactor. BH4 
could therefore account as an EDRF during prolonged 
inflammation marking the third switch, i.e. the switch 
from NO as an EDRF under physiological to BH4 as an 
EDRF under inflammatory conditions. As emphasized, 
species differences exist with respect to iNOS expres-
sion in vascular endothelial cells. Thus, the switch 
from exclusive endothelial to exclusive smooth muscle 
NO production is not generally valid, and in other 
species (e.g. in rat and mouse) iNOS may be expressed 
in both the endothelial and the smooth muscle com-
partment. As a result, both NO and BH4 may coexist as 
EDRFs in these species under inflammatory conditions 
(Fig. 3B). 
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Experimental evidence for the switch model has 
been obtained both in vitro (B7; 123) as well as in vivo 
in rats .152 In healthy subjects in vivo, the early phase 
of inflammatory vasodilation may be mediated by 
eNOS activation due to increased amounts of BH4, 
(115) but the question whether the switch from eNOS 
to iNOS takes place in later stages remains open. 
Besides the induction ofBH4 biosynthesis in animal 
models of sepsis experimental data also indicate that 
inhibition of BH4 metabolism or removal by hemoper-
fusion may prevent hemodynamic alterations suggest-
ing the potential as novel therapeutic strategy against 
morbidity and mortality of septic shock.(153-156). 
Oxidative stress: interplay of oxygen-derived free 
radicals with NO and BH4 
Endothelial functions are disrupted by a wide vari-
ety of perturbations. "Endothelial dysfunction" is 
believed to be an early event and important contributor 
in the etiology of several human vascular diseases , e.g. 
atherosclerosis, ischemialreperfusion injury, and heart 
failure.(74;84) Besides loss of endothelial production 
and/or bioavailability of NO, a common denominator 
in these disorders comprises increased production of 
reactive oxygen intermediates (ROI), a class of mole-
cules that includes superoxide anions, hydrogen perox-
ide, and hydroxyl radicals . Under certain conditions, 
production of ROI may outweigh endogenous antioxi-
dant defense mechanisms, referred to as oxidative 
stress, and participate in the pathogenesis of cardio-
vascular disorders.( 157) Many enzymatic systems are 
potential sources of ROJ, which in tum can interact 
with vascular signaling systems and potentially oxi-
dize any molecule in a cell, causing DNA nicking and 
disruption, lipid peroxidation, and protein cross-link-
ing and degradation.(157-159) 
The level of intracellular BH4 is critical for the 
degree of ROI production by eNOS. Activation of 
purified eNOS in the presence of suboptimal levels of 
BH4 results in uncoupling of oxygen reduction and 
arginine oxidation as well as generation of increased 
amounts of ROJ,(51 ;52) a finding that was confirmed 
in vitro and in vivo.(160-163) The BH417 ,B-BH2 ratio 
seems to control superoxide generation by eNOS as 
oxidized derivatives of BH4 compete for binding and 
lead to enhanced ROI production implicating the redox 
state of the cofactor to be of central importance.(53) 
Therefore, decreased availability of BH4 may cause a 
shift in the balance between the production of protec-
tive NO and toxic ROI and contribute to endothelial 
dysfunction and oxidative vascular injury. Inte-
restingly, hydrogen peroxide itself may become a 
mediator of endothelium-dependent relaxations in 
states of BH4 deficiency in vitro,( 160) whereas super-
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oxide causes endothelium-dependent contractions 
mediated in part by chemical inactivation of NO (see 
below). 
Oxidative stress may contribute to impaired 
endothelium-dependent vasodilation through acceler-
ated NO degradation. Superoxide reacts with NO in a 
nearly diffusion limited reaction yielding peroxynitrite 
at a reaction rate more than 3 times faster than that for 
superoxide with SOD .(164) Since the interaction of 
superoxide anions with NO is extremely rapid, this 
may even occur under physiologic conditions, and NO 
availability may become markedly reduced by super-
oxide anions and probably other radicals. 
Peroxynitrite, a powerful oxidant with a relatively 
long half-life, is considered a primary reactive nitrogen 
species responsible for deletorious effects of NO. It is 
capable of hydroxylating and nitrating aromatic com-
pounds, and inducing cellular injury by lipid peroxida-
tion, DNA fragmentation, damage to proteins and 
plasma lipids, and depletion of important plasma 
antioxidants .( 49) 
As has been discussed, decreased availability of 
BH4 may increase oxidative stress , and a decrease in 
BH4 content in endothelial cells may indeed accelerate 
oxidative stress-induced endothelial cell . death; 
(165)conversely, oxidative stress may contribute to 
decreased availability of functional pteridine cofactor 
by oxidative reactions. Under physiological conditions 
in vitro, peroxynitrite specifically oxidizes BH4.(l66) 
Peroxynitrite-catalyzed oxidation of BH4 proceeds via 
two pathways from the quinoid 5,6-BH2 intermediate. 
In one, a direct rearrangement to the more stable dihy-
dro isomer 7,B-BH2 occurs, and this isomer may be 
reduced back to BH4. A large proportion of the quinoid 
5,6-BH2, however, loses its side-chain in the 6 position 
to form 7,8-dihydropterin, which can then be rapidly 
hydrated and converted to other species, including 
dihydroxanthoperin, thereby irreversibly losing cofac-
tor function. ( 166) Finally, this may result in a vicious 
circle since limited bioavailability of BH4 uncouples 
L-arginine oxidation and increases eNOS-dependent 
superoxide production. 
Autoxidation of BH4. In vitro, BH4 is susceptible to 
autoxidation in the presence of oxygen,(l67 -169) BH4 
may react with oxygen to yield oxidized pteridines and 
ROL( lO2; 170; l71) Experiments with SOD suggest 
that superoxide is both a product of BH4 autoxidation 
and accelerator of the autoxidative process.(l70) The 
distribution of oxidized pteridines is nearly identical to 
those formed after oxidation with peroxynitrite, again 
indicating that ROI are most likely involved in this 
process leading to irreversible loss of cofactor function 
of the pteridine.( 166) Evidence for autoxidation of 
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BH4 has also been obtained in isolated vessels in vitro, 
and exogenous BH4 regained the ability to stimulate 
endothelial NO synthesis anly after the addition of 
SOD.(102;109) Increased superoxide anions formed 
after BH4 autoxidation could also interact with NO 
resulting in peroxynitrite generation and additional 
subsequent oxidative destruction of BH4. These data 
imply that SOD may be critical for the effect of exoge-
nous BH4 on the vasculature, at least under experimen-
tal conditions. It is, therefore, noticable that in vascu-
lar endothelial cells increased endogenous BH4 synthe-
sis may be associated with simultanenous induction of 
SOD .( I72) However, it is important to remember that 
all these findings have been obtained in vitro, and the 
relevance for in vivo conditions remains yet to be clar-
ified. 
Effects of exogenous BH4. Beneficial effects of 
BH40n oxidative stress include specific actions, i.e. 
reduction ofROI generation by eNOS as well as rather 
unspecific mechanisms. Several studies confirm the 
potential of BH4, either in authentic form or given as 
sepiapterin, as antioxidant and scavenger of ROI, 
(173-178) see also reference (18) for review. 
In line with the hypothesis of unspecific ROI scav-
enging is the observation that other pteridines, which 
share antioxidant and/or radical scavenging properties 
but no cofactor function with BH4, also protect various 
cells against oxidative stress,(l8; 179-186) and the 7,8-
dihydrostucture of the pteridines was recognized to 
indicate strong scavenging potency. ( 187 -189) 
Antioxidants : interplay of BH4 with ascorbic acid 
(vitamin C) and folales? 
Ascorbic acid. Lower dietary intake or plasma lev-
els of ascorbic acid are associated with increased car-
diovascular events . Conversely, ascorbic acid 
improves endothelium-dependent vasodilation in 
patients with coronary artery disease, risk factors for 
atherosclerosis, or cluonic heart failure.( 190) Pre-
vention of oxidative modification of LDL, inhibition 
of leukocyte-endothelial cell interactions, and radical 
scavenging properties with prevented NO inactivation 
have been implicated,( 191) however, ascorbic acid 
may not compete effectively with NO for superoxide at 
physiologically relevant concentrations,(I92) and only 
results from studies using intraarterial ascorbic acid 
may be explained to a certain degree by superoxide 
scavenging. Another potential mechanism may depend 
on BH4. In vitro, intracellular BH4 levels are increased 
after treatment with ascorbic acid, (96;]93;194) and 
low concentrations of ascorbic acid enhance NO syn-
thesis only when BH4 was omitted from cell lysate 
assays.( 195) Likewise, pretreatment with ascorbic 
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acid, which by itself dose-dependently augmented 
acetylcholine-mediated blood flow, abolished benefi-
cial effects of BH4 on endothelium-dependent vasodi-
lation in vivo.(l12) The action of ascorbic acid does 
not seem to be mediated by increased BH4 biosynthe-
sis, nor by modification of the pteridine affinity of 
eNOS, but may be due to chemical stabilization ofBH4 
(96) thereby optimizing endothelial NO synthesis. 
Folates. Low serum folate levels are associated with 
an increased risk of cardiovascular events,( 196; 197) 
traditionally ascribed to the cofactor function for 
enzymes of homocysteine metabolism. Mechanisms 
contributing to vasculopathy include promotion of 
endothelial dysfunction, impaired regulation of EDRF 
and related nitrogen oxides, and decreased availability 
of NO.(l98-200) BII4 may inhibit superoxide produc-
tion induced by culturing of vascular cells with homo-
cysteine.(201) Folate efficiently reduces plasma homo-
cysteine levels and restores endothelial dysfunction 
induced by acute hyperhomocysteinemia.(202-205) In 
addition folate may improve endothelial function inde-
pendently of its homocysteine-lowering effect that 
may include a reduction of ROl production by eNOS 
and other enzymes and increased availability of 
NO.(206;207) Interestingly, 5-methyltetrahydrofolate 
(5-MTHF) enhanced NO production and decreased 
superoxide production of partially ptendine-repleted 
but not of pteridine-free eNOS suggesting 5-MHTF to 
support BH4 as cofactor of eNOS.(208) The exact 
intracellular mechanism remains unknown at present. 
Endothelial dysfunction and atherosclerosis 
Endothelial dysfunction occurs early during the 
pathogenesis of atherosclerosis, adds to alterations in 
vascular function and structure, and may be pivotal for 
the progress of atherosclerosis. Causes of endothelial 
dysfunction include elevated and modified low-densi-
ty lipoproteins (LDL), free radicals caused by cigarette 
smoking, hypertension, diabetes mellitus, genetic 
alterations, elevated plasma homocysteine concentra-
tions, infectious microorganisms, and other yet uniden-
tified factors. A number of these disorders are associ-
ated with reduced synthesis/availability or increased 
degradation of endothelium-derived NO, and abnormal 
vasoreactivity is seen before morphological changes of 
atherosclerosis are visible. A growing body of evi-
dence suggests increased production of ROI to be of 
pathophysiological importance contributing to inacti-
vation of NO and endothelial dysfunction. 
(84; 157;203;209-21]) 
In patients with cardiovascular risk factors or clini-
cally manifest atherosclerosis , exogenous L-arginine 
normalizes endothelium-dependent vasodilation and 
diminishes lesion formation.(74;84) The exact mecha-
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nism remain incompletely understood, but has mostly 
been attributed to an influence on eNOS activity. This 
is, at first glance, surprising since in vivo L-arginine 
concentrations appear to be well above the Km of 
eNOS for L-arginine,(212) and recently, it was sug-
gested that effects independent of the role of L-argi-
nine as substrate for eNOS may contribute as 
weIl.(212-216) A rapidly increasing number of studies 
demonstrates the potential of BH4 to reverse endothe-
lial dysfunction associated with risk factors leading to 
atherosclerosis or even in patients with manifest ather-
osclerosis and suggests that BH4 may be of pivotal sig-
nificance in the pathogenesis of this NO/oxidant 
imbalance. 
Diabetes mellitus. Endothelial dysfunction is a 
common feature in experimental and clinical diabetes 
mellitus, and increased leve ls of ROI, release of an 
endothelium-derived constricting factor, and decreased 
endothelial NO synthesis are likely contributors to its 
pathogenesis.(21 0;217-219) Only little infomlation is 
available concerning NOS activity, mRNA, and pro-
tein, but there is some evidence ofnomlal or increased 
mRNA and protein levels despite impaired endothelial 
function due to a decrement of eNOS activity and 
increased endothelial superoxide generation .(220;221) 
A lthough in vitro NO synthesis was impaired, nomlal 
NOS activity was measured in cell homogenates under 
optimal conditions excluding an intrinsic defect in 
eNOS in these animals.(222) 
Rat models of diabetes revealed an influence of the 
diabetic state on BH4 metabolism. In these animals de 
novo biosynthesis of BH4 as well as GTPCH and 
DHPR activities is reduced, and besides decreased BH4 
levels, increased concentrations of more oxidized 
forms are measured; in contrast, the BH4 salvage path-
way seems unaltered. Long-term oral treatment with 
BH4 increases GTPCH and eNOS activity without 
affecting eNOS protein or mRNA expression, 
improves endothelium-dependent relaxation, and nor-
malizes superoxide production, membrane lipid perox-
idation, and binding activity of redox-sensitive tran-
scription factors; beneficial effects have also been 
reported with the lipid-soluble pteridine derivative 6-
methyl-BH 4. In addition, insulin stimulates the synthe-
sis of BH4 through activation of GTPCH in these ani-
mals, (221 ;223-226) and the endothelium-mediated 
vasorelaxation caused by insulin itself may be depend-
ent on BH4. (227) The suggestion that BH4 biosynthe-
sis might be reduced in diabetic conditions is support-
ed by another study in LPS treated J774 
macrophages.(228) Hitherto only limited information 
about human diabetes is available, but recent investi-
gations indicate that BH4 improves vascular endothe-
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lial dysfunction also in patients with type 2 diabetes 
mellitus·CIl3) 
Smoking. Smoking has adverse effects on the vas-
cular endothelium, and endothelial dysfunction in 
chronic smokers that includes an impairment of basal 
and stimulated N O production is welI established. This 
impairment may be reversible on smoking cessation. 
Endothelial dysfunction of smokers is multifactorial 
and not entirely understood , but increased stress due to 
ROI is likely to be of central importance.(229) 
Irnmunostaining experiments suggest impairment of 
eNOS activity but not protein expression by smoking. 
An inhibition of eNOS by aromatic amines from the 
combustion of tobacco has been proposed.(230) Other 
contributing factors may include free radicals from 
smoke that may react to form peroxynitrite, and the 
induction of superoxide production as a result of 
autoxidation of polyhdroxyaromatic compounds;(112) 
these data suggest oxidation of BH4 as the underlying 
cause of eNOS dysfunction , however, a formal proof 
for this hypothesis is lacking at the moment. BH4 or 
sepiapterin improve endothelial dysfunction in human 
saphenous veins from smokers in vitro, and concomit-
tantly increased production of nitrite/nitrate and cGMP 
indicate restoration of L-arginine-NO-pathway activi-
ty.(230) BH4 also improves basal and endothelial-
dependent vasodilation of chronic smokers in vivo 
through a rather specific effect, most probably the 
reduction of NOS-derived ROI, and not by a nonspe-
cific antioxidant action .( 112) 
Hypertension. Endothelium-derived NO production 
has repeatedly been found to be impaired in essentia l 
hypertension. Oxidative stress plays an important role 
in the pathogenesis of hypertension, and besides other 
sources a dysfunctional eNOS has been identified as 
producer of superoxide.(203 ;210;23I ;232) In sponta-
neously hypertensive rats, exogenous BH. seemed not 
only to increase NO production but also to decrease 
levels of ROI although total biopterin levels in vessel 
walls were only slightly and non-significantly lower 
than in normotensive Wistar-Kyoto rats.(233) Only 
preliminary data are available on patients with essen-
tial hypertension. However, BH4 increased endotheli-
um-dependent vasodilation in forearms of such 
patients in a way that was abolished by an NOS 
inhibitor.(234 ) 
Hypercholesterolemia . Endothelial dysfunction in 
hypercholesterolemia with impaired NO generation 
has been associated with increased endothelial ROI 
production which is at least part caused by eNOS 
itself.(21 0;235) In patients with familial hypercholes-
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terolemia but without clinical signs of atherosclerosis, 
intraarterial administration of BH4 restored endotheli-
um-dependent vasodilation; the action was only tran-
sient, and discontinuation of BH4 infusion resulted in 
reoccurrence of impaired NO activity within 20 rnin-
utes .( 111) L-arginine is rate limiting in the L-arginine-
NO pathway in hypercholesterolemia, and L-arginine 
alone improves NO-dependent vasodilation in such 
patients.(235) However, L-arginine causes no further 
improvement in the presence of BH4 supplementation, 
indicating that functional BH4 deficiency may con-
tribute to the "L-arginine paradox" by decreasing the 
affinity of eNOS for L-arginine.(111) 
Clinically man!{est atherosclerosis. In severely ath-
erosclerotic mice lacking the apolipoprotein E and 
LDL receptor genes, BH4 slightly improved attenuated 
endothelium-dependent relaxation and, in combination 
with L-arginine, induced a pronounced enhancement 
of endothelium-dependent vas ore laxation whereas L-
arginine alone was ineffective.(236) In nitrogy1cerin-
tolerant rats, BH4 alone improved endothelium-
dependent vasodilation suggesting that altered 
bioavailability of BH4 may be of importance in this 
clinically relevant situation.(237) Interpretation of 
research on human atherosclerosis is hindered by the 
difficulty in obtaining true control vessels . However, 
there is evidence that basal NO release is impaired in 
atherosclerotic vessels,(238 ;239) and studies on 
human aortas indicate a dowruegulation of eNOS in 
endothelial cells overlying advanced atherosclerotic 
lesions.(240) These findings are supported by another 
study on arteries with advanced atherosclerosis 
obtained from patients undergoing carotid atherectomy 
or coronary bypass surgery in which eNOS protein and 
NO release was markedly diminished in luminal 
endothelial cells but not in endothelial cells of vasa 
vasorum inside the atherosclerotic plaque.(24 I ) 
Consistent with these findings, differences in NO 
release observed in normal and atherosclerotic seg-
ments of explanted vein grafts are mirrored by focally 
reduced eNOS expression specific to atherosclerotic 
sites .(242) Despite the recurring observation of eNOS 
dowruegulation endothelial cells of atherosclerotic 
vessels, several studies demonstrated the potential of 
BH4 to improve endothelium-dependent vasodilation 
in patients with manifest atherosclerosis; e.g. in isolat-
ed human coronary arterioles from patients with sig-
nificant coronary atherosclerosis,(239) and in vivo in 
patients with coronary artery disease.(243) Preliminary 
data also indicate the potential of BH4 to improve 
endothelium-dependent vasodilation and to reduce 
ROI generation in coronary arteries of patients with 
single or more cardiovascular risk factors but no sig-
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nificant coronary anery disease(244) and to enhance 
vasodilation in patients with atypical chest pain but 
angiographically normal coronary arteries .(245) 
Recent immunohistochemical studies demonstrated 
the expression of iNOS in human and experimental 
atherosclerosis and a predominant presence in 
advanced atherosclerotic plaques,(240;246-249) how-
ever, no study hitherto performed has addressed the 
effects of BH4 on iNOS in atherosclerotic plaques. 
Saphenous vein grafts. In saphenous vein segments 
from patients undergoing coronary artery bypass graft 
operations, BH4 roughly doubles actylcholine-induced 
vasorelaxation, indicating a dysfunctional endothelium 
already at the time of grafting.(250) Since in maturing 
vessel grafts endothelial NO synthesis may limit inti-
mal hyperplasia, an improved supply of BH4 could 
improve the patency of vessel grafts,(230) but long-
term studies will be required test this hypothesis . 
Taken together, BH4 improves endothelial dysfunc-
tion associated with several risk factors for atheroscle-
rosis or in manifest atherosclerosis. The biochemical 
background for a local functional BH4 deficiency in 
these disorders remains elusive, possible explanations 
include 1) increased oxidation ofBH4 due to enhanced 
oxidative stress, and 2) decreased biosynthesis of the 
pteridine. The latter mechanism is supported by in 
vitro data demonstrating that oxidized LDL inhibits 
GTPCH gene expression in cytokine-activated 
cells.(251 ) 
Endothelial dysfunction and chronic heart failure 
Abnormalities in endothelial function with impaired 
endothelium-dependent vasorelaxation have also been 
described in patients with chronic heart failure, and 
ROI have been implicated in its pathogene-
sis.(210;252) To date, only preliminary and inconsis-
tent data published in abstract form are available on the 
influence of BH4 on the vasculature in chronic heart 
failure. Whereas in one study an effect of BH4 on 
endothelium-dependent vasodilation was lacking, in 
another an improvement was found, (253 ;254) and 
clearly further work is needed to clarify the role of BH4 
in this clinically important disease. 
BH4 and hypertension 
The importance of eNOS for control of systemic 
and eventually pulmonary hypertension has been con-
firmed by eNOS knockout mice.(86) In the healthy 
vasculature, however, BH4 requires rather high con-
centrations for hypotensive effects, as discussed earli-
er. Notwithstanding, BH4 restores endothelial dysfunc-
tion associated with hypertension, and under certain 
experimental conditions the pteridine also has some 
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antihypertensive properties in animal models, e.g. in 
Male Sprague-Dawley rats fed high levels of fructose 
and uninephrectomized rats treated with deoxycorti-
costerone acetate and 1 % NaCl in the drinking water 
(DOCA-salt rats).(225;255) 
Involvement of BH4 in ischemia-reperfusion (IIR) 
injury and "IIR tolerance" 
Mechanisms of postischemic reperfusion (IIR) 
injUry remain incompletely understood, but oxidative 
stress due to excess endothelial generation ofROI after 
the restoration of blood supply is thought to be of 
major importance.(l58) In several animal models , 
exogenous sepiapterin, 6-methyl-BH4, or BH4 have 
shown beneficial effects on IIR injury.(256-261) In 
contrast, no study has investigated so far whether 
exogenous BH4 also improves IIR injury in man. 
Although evidence for a beneficial effect of BH. on 
fIR injUly is sound, only an indefinite idea about 
underlying processes exists and several mechanisms 
likely contribute. BH4 has potential activity as antioxi-
dant and scavenger ofROI in endothelial cells, and this 
unspecific property may be involved. Furthemlore, 
since experiments using inhibitors ofBH4 biosynthesis 
mimicked those from I1R experiments,(257;259) a 
decreased availability of functional pteridine cofactor 
is suspected ill vessels exposed to I1R. As stated earli-
er, eNOS mediated ROI generation is triggered and 
controlled by decreased av'ailability of BH4. 
Conversely, exogenous BH4 decreases superoxide lev-
els by unspecific scavenging and reduction of eNOS 
dysfuntion.(51 ;52) Indeed, exogenous BH4 may 
restore impaired eNOS fUllction and increase cGMP 
production after VR injury.(256;257;259) 
The biochemical basis of eNOS impairment 
remains elusive. Giraldez et al. proposed a model to 
explain loss of eNOS activity occurring only after 
polonged IIR. They suggested intracellular acidosis to 
trigger titration of a critical amino acid (step 1) which 
would lead to further altered protein conformation 
with a partially unfolded protein (step 2). These two 
steps may be potentially reversible upon reperfusion. 
However, in a final step, the unfolded protein confor-
mation would then be susceptible to proteolytic degra-
dation, leading to the irreversible loss of enzyme activ-
ity.(262) Experiments with purified nNOS showed that 
stabilization of the dimeric state by BH4 reduces inac-
tivation by ROI.(36) Although this remains to be for-
mally confirmed for the eNOS isofoml, recently 
increased total eNOS protein but decreased immunore-
activity for dimeric eNOS after experimental IIR was 
demonstrated, and the latter was restored by additional 
BH4.257 Being not only confirmative for intracellular 
depletion of BH4 after IIR, these data also suggest 
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depletion of BH. to be of central importance for the 
stepwise loss of eNOS activity. 
An unresolved issue remains how IIR injury affects 
BH4 metabolism and results in diminished functionali-
ty of the pteridine. Although decreased de novo BH4 
biosynthesis has been suggested,(257) the investiga-
tion was indirect; in fact, neither total biopterin con-
tents nor expression of genes/enzyme activities 
involved in BH4 biosynthesis/regeneration have ever 
been measured during or after experimental I/R injury. 
However, it is conceivable to assume that enhanced 
oxidative stress within endothelial cells may result in 
oxidation of BH4 and loss of cofactor function, as out-
lined above. 
Besides potentially disrupting and deleterious 
effects, I/R can also induce a series of events within 
hours or days that renders tissues more resistant to sub-
sequent IIR insults . Recently, a critical dependence on 
activation and translocation ofNF-kB for the develop-
ment of "I/R tolerance" in endothelial cells was 
demonstrated.(90) Although both anoxia/reperfusion 
challenges were followed by transient increases in total 
eNOS protein, only the first was associated with 
increased oxidative stress, whereas after the second 
reduced oxidative stress was paralleled by increased 
NO production whith complete dependence on de 
novo BH4 biosynthesis. It was suggested that NF-kB 
may contribute to the development of IlR tolerance by 
transactivating the GTPCH gene, and increased BH4 
levels would help to decrease subsequent 1t'R-induced 
cell damage.(90) 
Vascular NOS gene therapy: requirement for BH4 
Recently, NOSs have emerged as potential candi-
dates for vascular gene therapy to restore deficient 
endothelial NO production in a variety of cardiovascu-
lar diseases. NOS vascular gene transfer restores or 
augments NOS activity in the vessel wall, modulates 
vascular smooth muscle cell biology, and leads to 
regression of early experimental atherosclerosis .(263) 
Only very limited information is available at present 
about the role of BH4 in NOS gene transfer. Almost all 
studies showed increased NO production after gene 
transfer without the addition of BH4. However, some 
data indicate that BH4 might be a limiting factor for the 
efficiency of NOS gene therapy. This is conceivable 
because 1) even under physiologic conditions BH4 has 
the potential to regulate vascular NO production, and 
2) smooth muscle cells which are likely target cells do 
not constitutively synthesize BH4. In vitro, for exam-
ple, additional sepiapterin significantly enhanced NO 
production in human vascular cells transfected with 
nNOS and porcine coronary artery smooth muscle 
cells transfected with eNOS.(104;264) In another 
PteridinesIYol. 12!No. 3 
108 
study, human iNOS was transfered into vascular cells 
and isolated blood vessels. Whereas transfected 
smooth muscle cells strongly dependent on exogenous 
BH4 for NO synthesis, pulmonary endothelial cells 
obviously did not, and only porcine arteries transfect-
ed with human iNOS following balloon injury exhibit-
ed an increase in activity of NO-cGMP pathway over 
control vessels in a BH4 dependent fashion clearly 
indicating that the level of functional BH4 already 
present is a denominator whether exogenous BH4 has 
any additive effect.(265) Today, functional BH4 trans-
fection by use of human GTPCH expression plasmids 
is technically feasible and reconstitutes near-maximal 
iNOS activity. Importantly, GTPCH and iNOS 
enzymes do not have to coexist within the same cells 
supporting the concept that BH4 produced in one cells 
is accessible to neighbouring NOS expressing 
cells .( I 07) Consequently, first in vitro and ex vivo 
experiments confirm the potential of co-transfected 
BH4 to enhance NO production achieved by gene 
transfe •. (266;267) Although further verification is 
awaited, it is clearly indicated that supplementation 
with BH4 may be required for efficient vascular NOS 
gene therapy, especially when the iNOS gene is trans-
rected. It remains to be clarified whether cotransfec-
tion ofGTPCH gene or direct administration ofBH4 is 
preferable to deliver BH4 in these therapeutic settings. 
Is BH4 critical for synthesis and biological effects of 
VEG F-A ? 
1be vascular endothelial growth factor (VEGF) 
family consists of several members of angiogenetic 
growth factors among those VEGF-A has been best 
characterized.(268) The effect of NO on VEGF-A 
remains a matter of some debate . It has convincingly 
been demonstrated, however, that NO upregulates 
VEGF-A synthesis.(269) Conversely, actions of 
VEGF-A arc partly mediated by endothelium-derived 
NO,(270-278) and long-term exposure of endothelial 
cells to VEGF-A increases eNOS mRNA and protein 
levels.(279;280) First evidence for a modulatory role 
of BH4 on cytokine-induced VEGF-A biosynthesis has 
recently been provided.(269) If confirmed, this finding 
may have some clinical significance as VEGF-A gene 
transfer is intensively studied as novel therapeutic 
approach to achieve angiogenesis in patients with 
symptomatic cardiovascular ischemic diseases .(281) 
In vivo data suggest a defective endothelial NO syn-
thesis to be a limiting factor for the effect of VEGF-
A.(282) Since in atherosclerotic vessels a functional 
BH4 deficiency contributes to dysfunctional endothe-
lial NO production, one may speculate that results of 
VEGF plasmid transfections could be critically 
dependent on local BH4 levels, and that restoration of 
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BH. (pharmacologi.cally or by co-transfection with 
BH4-encoding genes) could be a prerequisite for opti-
mal treatment. 
BH4 and the pulmonary circulation 
Pulmonary endothelial cell changes occur early in 
most clinical and experimental forms of acute lung 
injury.(283) Abnormalities of endothelial function 
associated with an imbalance in the expression of 
endothelium-derived vasoactive substances, including 
reduced expression of eNOS and subsequent dimin-
ished NO production, have been demonstrated in a 
number of pulmonary diseases such as primary and 
secondary pulmonary hypertension, cinonic obstruc-
tive lung disease, cardiopulmonary bypass, and con-
gestive heart failure . (284-287) 
Surprising to note the minimal knowledge about 
effects of BH. in the lung. Although it is comprehensi-
ble to assume a regulation of pteridine synthesis simi-
lar to that in eXh·apulmonary tissues, experimental data 
to support this hypothesis are sparse. (59;149 ; 155; 
288) So far, pathophysiologic conditions associated 
with local BH4 deficiencies have not been described in 
the pulmonary circulation at alL Conversely, exoge-
nous BH4 improved pulmonary endothelial dysfunc-
tion following I /R injury by a mechanism involving the 
NO-cGMP pathway.(2S6) Further studies sbould clari-
fy the role of BH4 in other lung dIsorders and the 
potential to improve them. In a prelimi.nary study it 
was demonstrated that BH4 application by inhalation IS 
feasible, weB tolerated, and results in local resorption 
ofBH4 in the lung with subsequent increases in plasma 
and urinary BH4 levels but without alteration of sys-
temic hemodynarnics .(114) Thus, inhalational BHA 
may offer a basic tool for investigations on restoration 
of pulmonary endothelial dysfunction in future , and it 
remains to be seen whether local administration ofBH4 
by inhalation might be advantageous over systemic 
administration to achieve a therapeutic effect on 
endothelial dysfunction in the lung. 
Conclusions 
After more then a century of research on pteridine 
compounds it is now well established that BH4 is of 
central importance for vascular functions in health and 
disease. BH4 regulates vasomotion, modulates oxida-
tive stress both by decreasing NOS-induced ROI gen-
eration and by unspecific ROI scavenging properties, 
is involved in effects of other pivotal antioxidants, and 
may be required in the signaling pathway of cellular 
mitogens and growth factors. A hitherto only uncom-
pletely understood "BH4-deficiency" has been impli-
cated in a number of acquired vascular disorders, and 
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first clinical studies show promise with short-term 
BH4-modifying treatment strategies. However, effects 
of long-term treatment with BH4 are largely unknown 
and are eagerly awaited to answer the question whether 
BH4, either supplemented as drug or via gene therapy, 
has the potential to prevent cardiovascular disease or to 
modify its clinical course. 
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